The antiviral activity of poly-γ-glutamic acid, a polypeptide secreted by Bacillus sp., through induction of CD14-dependent type I interferon responses

Biomaterials. 2013 Dec;34(37):9700-8. doi: 10.1016/j.biomaterials.2013.08.067. Epub 2013 Sep 6.

Abstract

Poly-γ-glutamic acid (γ-PGA) is an anionic polypeptide secreted by Bacillus sp. that has been shown to activate immune cells through interactions with toll-like receptor 4 (TLR4). However, its ability to induce the type I interferon (IFN) response has not yet been characterized. Here, we demonstrate that γ-PGA induces type I IFN signaling pathway via the TLR4 signaling pathway. The induction required both myeloid differentiation factor 2 (MD2) and the pattern-recognition receptor CD14, which are two TLR4-associated accessory proteins. The γ-PGA with high molecular weights (2000 and 5000 kDa) was able to activate the subsequent signals through TLR4/MD2 to result in dimerization of IRF-3, a transcription factor required for IFN gene expression, leading to increases in mRNA levels of the type I IFN-response genes, 2'-5' OAS and ISG56. Moreover, γ-PGA (2000 kDa) displayed an antiviral activity against SARS coronavirus and hepatitis C virus. Our results identify high-molecular weight γ-PGA as a TLR4 ligand and demonstrate that γ-PGA requires both CD14 and MD2 for the activation of type I IFN responses. Our results suggest that the microbial biopolymer γ-PGA may have therapeutic potential against a broad range of viruses sensitive to type I IFNs.

Keywords: Antiviral agent; Hepatitis C virus; Interferon; Poly-γ-glutamic acid; SARS coronavirus; TLR4.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / metabolism
  • Antiviral Agents / therapeutic use*
  • Bacillus / metabolism
  • Cell Line
  • HEK293 Cells
  • Hepacivirus / drug effects*
  • Hepatitis C / drug therapy
  • Humans
  • Interferon Type I / immunology*
  • Lipopolysaccharide Receptors / immunology*
  • Mice
  • Polyglutamic Acid / analogs & derivatives*
  • Polyglutamic Acid / metabolism
  • Polyglutamic Acid / therapeutic use
  • Severe Acute Respiratory Syndrome / drug therapy
  • Severe acute respiratory syndrome-related coronavirus / drug effects*
  • Toll-Like Receptor 4 / immunology

Substances

  • Antiviral Agents
  • Interferon Type I
  • Lipopolysaccharide Receptors
  • Toll-Like Receptor 4
  • poly(gamma-glutamic acid)
  • Polyglutamic Acid